Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

guerbet - ioxitalamate meglumine 660,3 mg/ml - eq. ioxitalamic acid 506,7 mg/ml - solution for injection - 300 mg i/ml - ioxitalamate meglumine 660.3 mg/ml - ioxitalamic acid

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

guerbet - ioxitalamate meglumine 660,3 mg/ml - eq. ioxitalamic acid 506,7 mg/ml - solution for injection - 300 mg i/ml - ioxitalamate meglumine 660.3 mg/ml - ioxitalamic acid

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

guerbet - ioxitalamate meglumine 660,3 mg/ml - eq. ioxitalamic acid 506,7 mg/ml - solution for injection - 300 mg i/ml - ioxitalamate meglumine 660.3 mg/ml - ioxitalamic acid

United States - English - NLM (National Library of Medicine)

covetrus - flunixin meglumine (unii: 8y3jk0jw3u) (flunixin - unii:356ib1o400) - horse:  flunixin meglumine injectable solution is recommended for the alleviation of inflammation and pain associated with muscoskeletall disorders in the horse. it is also recommended for the alleviation of visceral pain associated with colic in the horse. cattle: flunixin meglumine injectable solution is indicated for the control of pyrexia associated with bovine respiratory disease, endotoxemia and acute bovine mastitis. flunixin meglumine injectable solution is also indicated for the control of inflammation in endotoxemia. contraindications horse: there are no known contraindications to this drug when used as directed. intra-arterial injection should be avoided. horses inadvertently injected intra-arterially can show adverse reactions. signs can be ataxia, incoordination, hyperventilation, hysteria, and muscle weakness. signs are transient and disappear without antidotal medication within a few minutes. do not use in horses showing hypersensitivity to flunixin meglumine. cattle: nsaids inhibit production of prostaglandins which are important in signaling the initiation of parturition. the use of flunixin can delay parturition and prolong labor which may increase the risk of stillbirth. do not use flunixin meglumine injectable solution within 48 hours of expected parturition. do not use in animals showing hypersensitivity to flunixin meglumine. use judiciously when renal impairment or gastric ulceration are suspected. safety horse: a 3-fold intramuscular dose of 1.5 mg/lb of body weight daily for 10 consecutive days was safe. no changes were observed in hematology, serum chemistry, or urinalysis values. intravenous dosages of 0.5 mg/lb daily for 15 days; 1.5 mg/lb daily for 10 days; and 2.5 mg/lb daily for 5 days produced no changes in blood or urine parameters. no injection site irritation was observed following intramuscular injection of the 0.5 mg/lb recommended dose. some irritation was observed following a 3-fold dose administered intramuscularly. cattle: no flunixin-related changes (adverse reactions) were noted in cattle administered a 1x (2.2 mg/kg; 1.0 mg/lb) dose for 9 days (three times the maximum clinical duration). minimal toxicity manifested itself at moderately elevated doses (3x and 5x) when flunixin was administered daily for 9 days, with occasional findings of blood in the feces and/or urine. discontinue use if hematuria or fecal blood are observed.

Canada - English - Health Canada

avir pharma inc. - gadopentetate dimeglumine - solution - 469mg - gadopentetate dimeglumine 469mg - miscellaneous therapeutic agents

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - gadoterate meglumine (unii: l0nd3981ag) (gadolinium cation (3+) - unii:azv954tz9n) - gadoterate meglumine injection is a gadolinium-based contrast agent indicated for intravenous use with magnetic resonance imaging (mri) in brain (intracranial), spine and associated tissues in adult and pediatric patients (including term neonates) to detect and visualize areas with disruption of the blood brain barrier (bbb) and/or abnormal vascularity. history of clinically important hypersensitivity reactions to gadoterate meglumine injection [see warnings and precautions (5.2)] . risk summary gbcas cross the human placenta and result in fetal exposure and gadolinium retention. the human data on the association between gbcas and adverse fetal outcomes are limited and inconclusive (see data) . in animal reproduction studies, there were no adverse developmental effects observed in rats or rabbits with intravenous administration of gadoterate meglumine during organogenesis at doses up to 16 and 10 times, respectively, the recommended human dose (see data) . because of the potential risks of gadolinium to the fetus, use gadoterate meglumine injection only if imaging is essential during pregnancy and cannot be delayed. the estimated background risk of major birth defects and miscarriage for the indicated population(s) are unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20% respectively. data human data contrast enhancement is visualized in the placenta and fetal tissues after maternal gbca administration. cohort studies and case reports on exposure to gbcas during pregnancy have not reported a clear association between gbcas and adverse effects in the exposed neonates. however, a retrospective cohort study, comparing pregnant women who had a gbca mri to pregnant women who did not have an mri, reported a higher occurrence of stillbirths and neonatal deaths in the group receiving gbca mri. limitations of this study include a lack of comparison with non-contrast mri and lack of information about the material indication for mri. overall, these data preclude a reliable evaluation of the potential risk of adverse fetal outcomes with the use of gbcas in pregnancy. animal data gadolinium retention gbcas administered to pregnant non-human primates (0.1 mmol/kg on gestational days 85 and 135) result in measurable gadolinium concentration in the offspring in bone, brain, skin, liver, kidney, and spleen for at least 7 months. gbcas administered to pregnant mice (2 mmol/kg daily on gestational days 16 through 19) result in measurable gadolinium concentrations in the pups in bone, brain, kidney, liver, blood, muscle, and spleen at one month postnatal age. reproductive toxicology gadoterate meglumine was administered in intravenous doses of 0, 2, 4 and 10 mmol/kg/day [3, 7 and 16 times the recommended human dose (rhd) based on body surface area (bsa)] to female rats for 14 days before mating, throughout the mating period and until gestation day (gd) 17. pregnant rabbits were administered gadoterate meglumine in intravenous doses of 0, 1, 3 and 7 mmol/kg/day ( 3, 10 and 23 times the rhd based on bsa) from gd6 to gd19. no effects on embryo-fetal development were observed at doses up to 10 mmol/kg/day in rats and 3 mmol/kg/day in rabbits. maternal toxicity was observed in rats at 10 mmol/kg/day and in rabbits at 7 mmol/kg/day. this maternal toxicity was characterized in rats by a slightly lower litter size and gravid uterus weight compared to the control group, and in rabbits by a reduction in body weight and food consumption. risk summary there are no data on the presence of gadoterate in human milk, the effects on the breastfed infant, or the effects on milk production. however, published lactation data on other gbcas indicate that 0.01 to 0.04% of the maternal gadolinium dose is present in breast milk. additionally, there is limited gbca gastrointestinal absorption in the breast-fed infant. gadoterate is present in goat milk (see data) . the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for gadoterate meglumine injection and any potential adverse effects on the breastfed infant from gadoterate meglumine injection or from the underlying maternal condition. data nonclinical data demonstrate that gadoterate is detected in goat milk in amounts less than 0.1% of the dose intravenously administered. furthermore, in rats, absorption of gadoterate via the gastrointestinal tract is poor (1.2% of the administered dose was absorbed and eliminated in urine). the safety and efficacy of gadoterate meglumine at a single dose of 0.1 mmol/kg have been established in pediatric patients from birth (term neonates ≥ 37 weeks gestational age) to 17 years of age based on clinical data in 133 pediatric patients 2 years of age and older, and clinical data in 52 pediatric patients birth to less than 2 years of age that supported extrapolation from adult data [see clinical studies (14)] . adverse reactions in pediatric patients were similar to those reported in adults [see adverse reactions (6.1)] . no dosage adjustment according to age is necessary in pediatric patients [see dosage and administration (2.1), pharmacokinetics (12.3)] . the safety of gadoterate meglumine has not been established in preterm neonates. no cases of nsf associated with gadoterate meglumine or any other gbca have been identified in pediatric patients age 6 years and younger [see warnings and precautions (5.1)] . normal estimated gfr (egfr) is approximately 30 ml/minute/1.73m2 at birth and increases to adult values by 2 years of age. juvenile animal data single and repeat-dose toxicity studies in neonatal and juvenile rats did not reveal findings suggestive of a specific risk for use in pediatric patients including term neonates and infants. in clinical studies of gadoterate meglumine, 900 patients were 65 years of age and over, and 304 patients were 75 years of age and over. no overall differences in safety or efficacy were observed between these subjects and younger subjects. in general, use of gadoterate meglumine injection in elderly patients should be cautious, reflecting the greater frequency of impaired renal function and concomitant disease or other drug therapy. no age-related dosage adjustment is necessary. no gadoterate meglumine injection dosage adjustment is recommended for patients with renal impairment. gadoterate can be removed from the body by hemodialysis [see warnings and precautions (5.1) and clinical pharmacology (12.3) ].

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - gadoterate meglumine (unii: l0nd3981ag) (gadolinium cation (3+) - unii:azv954tz9n) - gadoterate meglumine injection is a gadolinium-based contrast agent indicated for intravenous use with magnetic resonance imaging (mri) in brain (intracranial), spine and associated tissues in adult and pediatric patients (including term neonates) to detect and visualize areas with disruption of the blood brain barrier (bbb) and/or abnormal vascularity. history of clinically important hypersensitivity reactions to gadoterate meglumine injection [see warnings and precautions (5.2)] . risk summary gbcas cross the human placenta and result in fetal exposure and gadolinium retention. the human data on the association between gbcas and adverse fetal outcomes are limited and inconclusive (see data) . in animal reproduction studies, there were no adverse developmental effects observed in rats or rabbits with intravenous administration of gadoterate meglumine during organogenesis at doses up to 16 and 10 times, respectively, the recommended human dose (see data) . because of the potential risks of gadolinium to the f

United States - English - NLM (National Library of Medicine)

guardian drug company - diatrizoate meglumine (unii: 3x9mr4n98u) (diatrizoic acid - unii:5uvc90j1lk), diatrizoate sodium (unii: v5403h8vg7) (diatrizoic acid - unii:5uvc90j1lk) - diatrizoate meglumine and diatrizoate sodium solution is indicated for radiographic examination of segments of the gastrointestinal tract (esophagus, stomach, proximal small intestine, and colon). the preparation is particularly indicated when a more viscous agent such as barium sulfate, which is not water-soluble, is not feasible or is potentially dangerous. diatrizoate meglumine and diatrizoate sodium solution may also be used as an adjunct to contrast enhancement is computed tomography of the torso (body imaging); the preparation is indicated, in conjunction with intravenous administration of a radiopaque contrast agent, when unenhanced imaging may not provide sufficient definition in distinguishing normal loops of bowel from adjacent organs or areas of suspected pathology. do not administer to patients with a known hypersensitivity to diatrizoate meglumine and diatrizoate sodium solution or any of its components.

Australia - English - Department of Health (Therapeutic Goods Administration)

reach pharmaceuticals pty ltd - fosaprepitant dimeglumine, quantity: 245.3 mg (equivalent: fosaprepitant, qty 150 mg) - injection, powder for - excipient ingredients: lactose; polysorbate 80; hydrochloric acid; sodium hydroxide; disodium edetate - fosaprepitant msn, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of:,? highly emetogenic cancer chemotherapy (see section 4.2 dose and method of administration),? moderately emetogenic cancer chemotherapy (see section 4.2 dose and method of administration).

United States - English - NLM (National Library of Medicine)

camber pharmaceuticals, inc. - diatrizoate meglumine (unii: 3x9mr4n98u) (diatrizoic acid - unii:5uvc90j1lk), diatrizoate sodium (unii: v5403h8vg7) (diatrizoic acid - unii:5uvc90j1lk) - diatrizoate meglumine and diatrizoate sodium solution is indicated for radiographic examination of segments of the gastrointestinal tract (esophagus, stomach, proximal small intestine, and colon). the preparation is particularly indicated when a more viscous agent such as barium sulfate, which is not water-soluble, is not feasible or is potentially dangerous. diatrizoate meglumine and diatrizoate sodium solution may also be used as an adjunct to contrast enhancement in computed tomography of the torso (body imaging); the preparation is indicated, in conjunction with intravenous administration of a radiopaque contrast agent, when unenhanced imaging may not provide sufficient definition in distinguishing normal loops of bowel from adjacent organs or areas of suspected pathology. do not administer to patients with a known hypersensitivity to diatrizoate meglumine and diatrizoate sodium solution or any of its components.